News

Neurim’s satellite symposium at IPSA 2026
Apr 10, 2026
Neurim’s satellite symposium at IPSA 2026

We would like to express our gratitude to the attendees of our satellite symposium “Toward an integrated framework for treating insomnia in children with NDDs”, and to the symposium faculty […]

Read more
Neurim Partners Meeting 2026
Mar 24, 2026
Neurim Partners Meeting 2026

A great global meeting is built on collaboration between partners. Bringing our global network together is always a top priority at Neurim, and our 2026 Partners Meeting was our most impactful […]

Read more
New Partnership with KYE Pharmaceuticals
Jan 21, 2026
New Partnership with KYE Pharmaceuticals

We’re pleased to share that Neurim Pharmaceuticals has signed an exclusive licensing and distribution agreement with KYE Pharmaceuticals Inc. to bring Slenyto to the Canadian market. This partnership marks a […]

Read more
Neurim Pharmaceuticals at the EAPS 2025 Congress
Oct 30, 2025
Neurim Pharmaceuticals at the EAPS 2025 Congress

Join Neurim Pharmaceuticals at the EAPS 2025 Congress in Lisbon and attend our satellite symposium, “Insomnia management in children with ASD & ADHD: An opportunity to improve developmental and behavioral […]

Read more
Slenyto is approved in Canada
Oct 21, 2025
Slenyto is approved in Canada

We are pleased to announce that Health Canada has granted marketing authorization for Slenyto®- Extended-Release Melatonin Formulation – as a Prescription Drug for Insomnia in Children with Autism Spectrum disorder […]

Read more